



Q4 2023 Highlights

January 31, 2024



Safe Harbor for Forward-Looking Statements and Use of Document

Safe Harbor for forward-looking statements:

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the first quarter and full year 2024; our financial performance; acquisitions; clinical trials; our business plans and product performance, and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this presentation. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences can be found in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed or to be filed with the Securities and Exchange Commission under the headings "Risk Factors" and "Safe Harbor for Forward-Looking Statements." Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Non-GAAP Measures:

This document contains non-generally accepted accounting principles in the United States (GAAP) measures (denoted with *) in talking about our Company's performance. The reconciliations of those non-GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to the end of this presentation or in our earnings release.

Operational net sales growth excludes the impact of foreign currency fluctuations. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments considered to be non-operational. Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations on Form 10-Q that we file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items.

Emerging Markets:

Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation.

Use of document:

This document contains certain highlights with respect to our fourth quarter and full year 2023 performance and developments and does not purport to be a complete summary of thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended December 31, 2023 located in the investor section of our website at www.bostonscientific.com and our Annual Report on Form 10-K for the year ended December 31, 2023 to be filed with the Securities and Exchange Commission.

Amounts reported in millions within this presentation are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.



Q4 2023 Highlights

Financial Results

- **Net sales growth:**
 - +14.9% reported, +14.5% operational*, +13.6% organic* Y/Y
- **Earnings per share:**
 - As reported: \$0.34 vs. \$0.09 Q4:22
 - Adjusted*: \$0.55 vs. \$0.45 Q4:22
- **Gross margin:**
 - As reported: 69.2%, +40 bps Y/Y
 - Adjusted*: 70.4%, (10) bps Y/Y
- **Operating margin:**
 - As reported: 15.7%, +330 bps Y/Y
 - Adjusted*: 26.6%, +90 bps Y/Y
- **Q1 2024 guidance vs. Q1 2023:**
 - As reported net sales growth: 7.5% - 9.5%
 - As reported EPS: \$0.29 - \$0.31
 - Organic* net sales growth: 7% - 9%
 - Adjusted EPS*: \$0.50 - \$0.52
- **FY 2024 guidance vs. FY 2023:**
 - As reported net sales growth: 8.5% - 9.5%
 - As reported EPS: \$1.38 - \$1.42
 - Organic* net sales growth: 8% - 9%
 - Adjusted EPS*: \$2.23 - \$2.27

Operational Highlights


- Received U.S. Food and Drug Administration (FDA) approval for the **FARAPULSE™ Pulsed Field Ablation (PFA) System** for the isolation of pulmonary veins in the treatment of drug-resistant, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF).
- Commenced enrollment of the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the **FARAPULSE PFA System** as a first-line treatment for persistent AF compared to anti-arrhythmic drug therapy.
- Welcomed the presentation of data from the MANIFEST-17K registry of more than 17,000 patients treated with the **FARAPULSE PFA System** that reinforce the real-world safety profile of the system.
- Enrollment commenced in the LAAOS-4 global research trial, which includes both the **WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device** and **WATCHMAN FLX Pro LAAC Device** and explores if patients with AF at highest risk for stroke benefit from a combined LAAC and oral anticoagulation therapy.
- Completed the acquisition of **Relievant Medsystems, Inc.**, a privately held medical technology company that has developed and commercialized the only U.S. FDA-cleared system, the **Intrasept® Intraosseous Nerve Ablation System**, for vertebrogenic pain.
- Announced **agreement to acquire Axonics, Inc.** (Nasdaq: AXNX), a publicly traded medical technology company that offers differentiated devices to treat urinary and bowel dysfunction, subject to customary closing conditions.



WW Net Sales by Segment and Business

Q4 2023 Reported Net Sales: \$3.725B

Net Sales by Business; Segment Percentage of Total Net Sales





MedSurg Performance Summary

Measure (\$ in millions)	Q4 2023	Q4 2022	Change Y/Y
Reported Net Sales	\$1,441M	\$1,297M	+11.1%
Adjusted Operating Margin*	35.4%	31.9%	+350 bps

* Represents operating income as a percentage of operational net sales, both based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. This measure is reported to the chief operating decision maker (CODM) for purposes of making decisions about allocating resources to the segment and assessing its performance. Prior period adjusted operating margin has been restated at constant currency rates to conform to current year presentation.

Q4 + FY 2023 Highlights

- **Endoscopy: Q4 2023 Global net sales +12.9% as reported, +12.2% operational*, +10.8% organic*; FY 2023 Global net sales +11.7% as reported, +12.3% operational*, +11.1% organic***
 - In Q4 2023, strong results were led by AXIOS™ and single-use scopes, both growing double digits vs Q4 2022.
 - All regions grew double digits in FY 2023, supported by the broad and deep portfolio, new product innovation and focus on commercial excellence.
- **Urology: Q4 2023 Global net sales +10.5% as reported, +9.9% operational*/organic*; FY 2023 Global net sales +10.8% as reported, +11.1% operational*/organic***
 - In FY 2023, global growth was led by Stone Management and Prosthetic Urology franchises.
 - Double digit FY 2023 growth within Prosthetic Urology was supported by our direct to patient campaign launched in 2023.
- **Neuromodulation: Q4 2023 Global net sales +8.0% as reported, +7.5% operational*, +2.6% organic*; FY 2023 Global net sales +6.4% as reported, +6.7% operational*, +5.3% organic***
 - The Pain franchise organic growth was flat in Q4 2023 vs Q4 2022, in line with expectations.
 - The Brain franchise grew double digits in both Q4 and FY 2023, led by the Vercise Genus portfolio powered by Image Guided Programming.



Cardiovascular Performance Summary

Measure (\$ in millions)	Q4 2023	Q4 2022	Change Y/Y
Reported Net Sales	\$2,285M	\$2,005M	+13.9%
Adjusted Operating Margin*	24.8%	23.0%	+180 bps

* Represents operating income as a percentage of operational net sales, both based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. This measure is reported to the CODM for purposes of making decisions about allocating resources to the segment and assessing its performance. Prior period adjusted operating margin has been restated at constant currency rates to conform to current year presentation.

Q4 + FY 2023 Highlights

- **Cardiology: Q4 2023 Global net sales +14.5% as reported, +14.2% operational*/organic*; FY 2023 Global net sales +13.1% as reported, +14.0% operational*, +13.6% organic***
 - **Interventional Cardiology Therapies: Q4 2023 Global net sales +9.3% as reported, +9.5% operational*/organic*; FY 2023 Global net sales +8.4% as reported, +10.4% operational*/organic***
 - FY 2023 Coronary Therapies franchise growth was driven by strong performance in our international regions and our Imaging franchise, globally.
 - The Structural Heart Valves franchise grew double digits in Q4 and FY 2023, led by the performance of ACURATE Neo2™ in Europe.
 - **Watchman: Q4 2023 Global net sales +22.9% as reported/operational*/organic*; FY 2023 Global net sales +25.1% as reported, +25.4% operational*/organic***
 - Record sales and strong utilization in all major markets in Q4 2023; 23% U.S. growth supported by initial WATCHMAN FLX Pro launch.
 - **Cardiac Rhythm Management: Q4 2023 Global net sales +6.2% as reported, +5.4% operational*/organic*; FY 2023 Global net sales +5.6% as reported, +5.9% operational*/organic***
 - In Core CRM, high-voltage franchise grew low-single digits, and low-voltage franchise grew mid-single digits in Q4 and FY 2023.
 - The Diagnostics franchise outpaced the market and grew double digits in FY 2023 vs FY 2022, driven by our broad portfolio.
 - **Electrophysiology: Q4 2023 Global net sales +43.9% as reported, +43.1% operational*/organic*; FY 2023 +36.7% as reported, +37.3% operational*, +32.7% organic***
 - U.S. Q4 2023 sales grew 40% organically, driven by our POLARx™ launch and ongoing momentum with Access Solutions technologies.
 - International growth accelerated into Q4 2023, growing 46% organically, fueled by improved FARAPULSE™ console supply.
- **Peripheral Interventions: Q4 2023 Global net sales +12.1% as reported, +12.2% operational*, +10.2% organic*; FY 2023 Global net sales +11.1% as reported, +12.6% operational*, +10.9% organic***
 - Arterial franchise growth was led by the performance of our Drug-Eluting portfolio in Q4 and FY 2023.
 - Interventional Oncology franchise grew low-double digits with strength across our portfolio of robust embolization technologies and cancer therapies.
 - In Venous franchise, Q4 and FY 2023 growth was led by Varithena™, our market leading varicose vein technology.



Living Our Values

Shaping a healthier planet through solar power



Boston Scientific activated its first European virtual power purchase agreement with renewable energy developer BayWa r.e., helping the company make progress on its decarbonization targets.

To learn more, read our [press release](#).

Advancing care by addressing disparities



Camille Chang Gilmore, VP human resources and global chief diversity, equity and inclusion officer, discusses health disparities and how our Close the Gap initiative helps health systems take meaningful steps toward greater equity.

To learn more, visit [Triple Pundit](#).

Accelerating disability inclusion opportunities



Boston Scientific was named a Best Place to Work for Disability Inclusion. Jackie, a Quality systems engineer, shares how she thrives as her full self in the workplace.

To learn more, visit our [Newsroom](#).

RECENT AWARDS

**2023 S&P Global
Dow Jones Sustainability Index**

**2023 American
Opportunity Index**

**Human Rights Campaign
Corporate Equality Index**



Q4 & FY 2023 Net Sales vs. 2022

(\$ in millions)	Q4 2023 Reported Net Sales	FY 2023 Reported Net Sales	Organic* Growth	
			vs Q4 2022	vs FY 2022
Endoscopy	\$645	\$2,482	11%	11%
Urology	\$527	\$1,964	10%	11%
Neuromodulation	\$269	\$976	3%	5%
MedSurg	\$1,441	\$5,422	9%	10%
Interventional Cardiology Therapies	\$614	\$2,417	10%	10%
Watchman	\$345	\$1,274	23%	25%
Cardiac Rhythm Management	\$553	\$2,218	5%	6%
Electrophysiology	\$240	\$800	43%	33%
Cardiology	\$1,751	\$6,709	14%	14%
Peripheral Interventions	\$533	\$2,110	10%	11%
Cardiovascular	\$2,285	\$8,819	13%	13%
Total Company	\$3,725	\$14,240	14%	12%
Guidance Range <i>Disclosed October 26, 2023</i>			8 to 10 percent	~11 percent

Q4 2023 organic* growth vs. Q4 2022 excludes:

- Majority stake investment in Acotec Scientific Holdings Limited, closed February 20, 2023
- Endoscopy Pathology business, divested April 1, 2023
- Apollo Endosurgery, Inc., acquired April 4, 2023
- Relievant Medsystems, Inc., acquired November 17, 2023

FY 2023 organic* growth vs. FY 2022 excludes:

- Baylis Medical Company, Inc., acquired February 14, 2022
- Majority stake investment in Acotec Scientific Holdings Limited, closed February 20, 2023
- Endoscopy Pathology business, divested April 1, 2023
- Apollo Endosurgery, Inc., acquired April 4, 2023
- Relievant Medsystems, Inc., acquired November 17, 2023



Income Statement Information

Non-GAAP Reconciliation

Three Months Ended December 31, 2023 (unaudited)

Boston
Scientific

<i>In millions, except per share data</i>	GAAP Results	Amortization Expense	Acquisition/ Divestiture- Related Charges (Credits)	Restructuring and Restructuring -Related Net Charges (Credits)	Litigation- Related Net Charges (Credits)	Investment Portfolio Net Losses (Gains)	EU MDR Implementation Costs	Deferred Tax Expenses (Benefits)	Discrete Tax Items	Adjusted* Results
Net sales	\$ 3,725	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 3,725
Cost of products sold	1,146	—	9	22	—	—	11	—	—	1,104
Gross profit	2,579	—	(9)	(22)	—	—	(11)	—	—	2,621
<i>Gross margin</i>	69.2 %									70.4 %
Selling, general and administrative expenses	1,379	—	92	11	—	—	0	—	—	1,276
<i>SG&A as a percentage of sales</i>	37.0 %									34.2 %
Research and development expenses	363	—	14	0	—	—	4	—	—	344
<i>R&D as a percentage of sales</i>	9.7 %									9.2 %
Royalty expense	12	—	—	—	—	—	—	—	—	12
<i>Royalty expense as a percentage of sales</i>	0.3 %									0.3 %
Amortization expense	208	208	—	—	—	—	—	—	—	—
Contingent consideration net expense (benefit)	14	—	14	—	—	—	—	—	—	—
Restructuring net charges (credits)	19	—	—	19	—	—	—	—	—	—
	1,995	208	120	30	—	—	5	—	—	1,631
Operating Income (loss)	584	(208)	(129)	(52)	—	—	(16)	—	—	990
<i>Operating margin</i>	15.7 %									26.6 %
Other income (expense):										
Interest expense	(65)	—	—	—	—	—	—	—	—	(65)
Other, net	(14)	—	0	—	—	0	—	—	—	(14)
Income (loss) before taxes	505	(208)	(129)	(52)	—	0	(16)	—	—	911
Income tax expense (benefit)	1	(31)	(75)	(8)	(1)	2	(2)	44	(18)	91
Net Income (loss)	504	(178)	(54)	(43)	1	(2)	(14)	(44)	18	819
Preferred stock dividends	—	—	—	—	—	—	—	—	—	—
Net income (loss) attributable to noncontrolling interests	(0)	(2)	—	—	—	—	—	—	—	2
Net Income (loss) attributable to Boston Scientific common stockholders	\$ 504	\$ (176)	\$ (54)	\$ (43)	\$ 1	\$ (2)	\$ (14)	\$ (44)	\$ 18	\$ 817
Net Income (loss) per diluted common share	\$ 0.34	\$ (0.12)	\$ (0.04)	\$ (0.03)	\$ 0.00	\$ (0.00)	\$ (0.01)	\$ (0.03)	\$ 0.01	\$ 0.55
Weighted average diluted shares outstanding	1,476.9	1,476.9	1,476.9	1,476.9	1,476.9	1,476.9	1,476.9	1,476.9	1,476.9	1,476.9



Income Statement Information

Non-GAAP Reconciliation

Year Ended December 31, 2023 (unaudited)

Boston
Scientific

<i>In millions, except per share data</i>	GAAP Results	Amortization Expense	Intangible Asset Impairment Charges	Acquisition/Divestiture-Related Charges (Credits)	Restructuring and Restructuring-Related Net Charges (Credits)	Litigation-Related Net Charges (Credits)	Investment Portfolio Net Losses (Gains)	EU MDR Implementation Costs	Deferred Tax Expenses (Benefits)	Discrete Tax Items	Adjusted* Results
Net sales	\$ 14,240	—	—	—	—	—	—	—	—	—	\$ 14,240
Cost of products sold	4,345	—	—	53	77	—	—	47	—	—	4,167
Gross profit	9,896	—	—	(53)	(77)	—	—	(47)	—	—	10,073
<i>Gross margin</i>	69.5 %										70.7 %
Selling, general and administrative expenses	5,190	—	—	210	35	—	—	0	—	—	4,945
<i>SG&A as a percentage of sales</i>	36.4 %										34.7 %
Research and development expenses	1,414	—	—	46	3	—	—	21	—	—	1,344
<i>R&D as a percentage of sales</i>	9.9 %										9.4 %
Royalty expense	46	—	—	—	—	—	—	—	—	—	46
<i>Royalty expense as a percentage of sales</i>	0.3 %										0.3 %
Amortization expense	828	828	—	—	—	—	—	—	—	—	—
Intangible asset impairment charges	58	—	58	—	—	—	—	—	—	—	—
Contingent consideration net expense (benefit)	58	—	—	58	—	—	—	—	—	—	—
Restructuring net charges (credits)	69	—	—	—	69	—	—	—	—	—	—
Litigation-related net charges (credits)	(111)	—	—	—	—	(111)	—	—	—	—	—
	7,553	828	58	314	107	(111)	—	21	—	—	6,335
Operating Income (loss)	2,343	(828)	(58)	(367)	(185)	111	—	(69)	—	—	3,738
<i>Operating margin</i>	16.5 %										26.3 %
Other income (expense):											
Interest expense	(265)	—	—	—	—	—	—	—	—	—	(265)
Other, net	(93)	—	—	(6)	—	—	(21)	—	—	—	(66)
Income (loss) before taxes	1,985	(828)	(58)	(373)	(185)	111	(21)	(69)	—	—	3,407
Income tax expense (benefit)	393	(115)	(4)	(21)	(29)	23	3	(10)	155	8	382
Net Income (loss)	\$ 1,592	\$ (713)	\$ (54)	\$ (352)	\$ (156)	\$ 88	\$ (24)	\$ (59)	\$ (155)	\$ (8)	\$ 3,025
Preferred stock dividends	(23)	—	—	—	—	—	—	—	—	—	(23)
Net income (loss) attributable to noncontrolling interests	(1)	(4)	—	—	—	—	—	—	—	—	4
Net Income (loss) attributable to Boston Scientific common stockholders	1,570	\$ (709)	\$ (54)	\$ (352)	\$ (156)	\$ 88	\$ (24)	\$ (59)	\$ (155)	\$ (8)	\$ 2,999
Net Income (loss) per diluted common share	\$ 1.07	\$ (0.48)	\$ (0.04)	\$ (0.24)	\$ (0.11)	\$ 0.06	\$ (0.02)	\$ (0.04)	\$ (0.11)	\$ (0.01)	\$ 2.05
Weighted average diluted shares outstanding	1,463.5	1,463.5	1,463.5	1,463.5	1,463.5	1,463.5	1,463.5	1,463.5	1,463.5	1,463.5	1,463.5

For the year ended December 31, 2023, the effect of assuming the conversion of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income attributable to common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.



Working Capital & Cash Flow Metrics

Days Sales Outstanding (DSO)

Dec 2023	Sept 2023	Jun 2023	Mar 2023	Dec 2022
55	55	54	55	56

Adjusted Free Cash Flow*

Q4 2023	Q4 2022	FY2023	FY2022
\$886M	\$776M	\$2,428M	\$2,066M

Days Inventory on Hand (DIOH)

Dec 2023	Sept 2023	Jun 2023	Mar 2023	Dec 2022
199	201	194	177	170

Capital Expenditures

Q4 2023	Q4 2022	FY2023	FY2022
\$267M	\$212M	\$711M	\$588M



Use of Non-GAAP Measures

To supplement Boston Scientific's consolidated financial statements presented on a GAAP basis, the Company discloses certain non-GAAP financial measures. These measures are not in accordance with generally accepted accounting principles in the United States.

A reconciliation of these measures to the corresponding GAAP measures follows in the Appendices. In addition, an explanation of the ways in which Boston Scientific management uses these supplemental non-GAAP measures to evaluate its business and the substantive reasons why Boston Scientific management believes that these measures provide useful information to investors is included under "Use of Non-GAAP Financial Measures" in the company's most recent earnings release filed with the SEC on Form 8-K. This information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.



Appendix A

Net Sales Detail



Appendix A - Net Sales Detail - MedSurg

Three Months Ended December 31, 2023 and 2022

			Year-over-Year Change		
(in millions)	Q4 2023	Q4 2022	Reported Basis	Impact of Foreign Currency	Operational Basis
MEDSURG SEGMENT:					
ENDOSCOPY					
UNITED STATES	\$ 394	\$ 349	12.9 %	— %	12.9 %
INTERNATIONAL	252	223	13.0 %	(1.8) %	11.2 %
WORLDWIDE	<u>\$ 645</u>	<u>\$ 571</u>	<u>12.9 %</u>	<u>(0.7) %</u>	<u>12.2 %</u>
UROLOGY					
UNITED STATES	\$ 362	\$ 336	7.9 %	— %	7.9 %
INTERNATIONAL	165	141	16.7 %	(1.9) %	14.8 %
WORLDWIDE	<u>\$ 527</u>	<u>\$ 477</u>	<u>10.5 %</u>	<u>(0.5) %</u>	<u>9.9 %</u>
NEUROMODULATION					
UNITED STATES	\$ 206	\$ 196	5.2 %	— %	5.2 %
INTERNATIONAL	63	53	18.5 %	(2.5) %	16.0 %
WORLDWIDE	<u>\$ 269</u>	<u>\$ 249</u>	<u>8.0 %</u>	<u>(0.5) %</u>	<u>7.5 %</u>



Appendix A - Net Sales Detail - Cardiovascular

Three Months Ended December 31, 2023 and 2022

(in millions)	Q4 2023	Q4 2022	Year-over-Year Change		
			As Reported Basis	Impact of Foreign Currency	Operational Basis
CARDIOVASCULAR SEGMENT:					
ICTx					
UNITED STATES	\$ 188	\$ 176	7.1 %	— %	7.1 %
INTERNATIONAL	426	386	10.3 %	0.3 %	10.6 %
WORLDWIDE	\$ 614	\$ 561	9.3 %	0.2 %	9.5 %
Watchman					
UNITED STATES	\$ 312	\$ 253	23.0 %	— %	23.0 %
INTERNATIONAL	33	27	21.7 %	0.0 %	21.7 %
WORLDWIDE	\$ 345	\$ 280	22.9 %	0.0 %	22.9 %
Cardiac Rhythm Management					
UNITED STATES	\$ 349	\$ 332	5.1 %	— %	5.1 %
INTERNATIONAL	204	189	8.2 %	(2.2) %	5.9 %
WORLDWIDE	\$ 553	\$ 521	6.2 %	(0.8) %	5.4 %
Electrophysiology					
UNITED STATES	\$ 110	\$ 79	40.4 %	— %	40.4 %
INTERNATIONAL	130	88	47.0 %	(1.5) %	45.5 %
WORLDWIDE	\$ 240	\$ 167	43.9 %	(0.8) %	43.1 %
CARDIOLOGY					
UNITED STATES	\$ 959	\$ 840	14.2 %	— %	14.2 %
INTERNATIONAL	792	690	14.9 %	(0.6) %	14.2 %
WORLDWIDE	\$ 1,751	\$ 1,529	14.5 %	(0.3) %	14.2 %
PERIPHERAL INTERVENTIONS					
UNITED STATES	\$ 292	\$ 266	9.6 %	— %	9.6 %
INTERNATIONAL	242	210	15.3 %	0.3 %	15.6 %
WORLDWIDE	\$ 533	\$ 476	12.1 %	0.1 %	12.2 %



Appendix A - Net Sales Detail - MedSurg

Year Ended December 31, 2023 and 2022

Boston
Scientific

			Year-over-Year Change		
(in millions)	FY 2023	FY 2022	As Reported Basis	Impact of Foreign Currency	Operational Basis
MEDSURG SEGMENT:					
ENDOSCOPY					
UNITED STATES	\$ 1,511	\$ 1,341	12.7 %	— %	12.7 %
INTERNATIONAL	970	880	10.2 %	1.4 %	11.7 %
WORLDWIDE	\$ 2,482	\$ 2,221	11.7 %	0.6 %	12.3 %
UROLOGY					
UNITED STATES	\$ 1,369	\$ 1,257	8.9 %	— %	8.9 %
INTERNATIONAL	595	516	15.2 %	1.3 %	16.5 %
WORLDWIDE	\$ 1,964	\$ 1,773	10.8 %	0.4 %	11.1 %
NEUROMODULATION					
UNITED STATES	\$ 736	\$ 715	3.0 %	— %	3.0 %
INTERNATIONAL	240	202	18.6 %	1.2 %	19.7 %
WORLDWIDE	\$ 976	\$ 917	6.4 %	0.3 %	6.7 %



Appendix A - Net Sales Detail - Cardiovascular

Year Ended December 31, 2023 and 2022

(in millions)			Year-over-Year Change				
			As Reported Basis	Impact of Foreign Currency	Operational Basis		
CARDIOVASCULAR SEGMENT:							
ICTx							
UNITED STATES	\$	743	\$	744	(0.1) %	— %	(0.1) %
INTERNATIONAL		1,674		1,485	12.7 %	3.0 %	15.7 %
WORLDWIDE	\$	2,417	\$	2,228	8.4 %	2.0 %	10.4 %
Watchman							
UNITED STATES	\$	1,155	\$	915	26.2 %	— %	26.2 %
INTERNATIONAL		119		103	15.4 %	3.1 %	18.5 %
WORLDWIDE	\$	1,274	\$	1,019	25.1 %	0.3 %	25.4 %
Cardiac Rhythm Management							
UNITED STATES	\$	1,405	\$	1,337	5.1 %	— %	5.1 %
INTERNATIONAL		813		763	6.5 %	0.7 %	7.2 %
WORLDWIDE	\$	2,218	\$	2,100	5.6 %	0.2 %	5.9 %
Electrophysiology							
UNITED STATES	\$	370	\$	275	34.6 %	— %	34.6 %
INTERNATIONAL		430		310	38.6 %	1.0 %	39.7 %
WORLDWIDE	\$	800	\$	585	36.7 %	0.6 %	37.3 %
CARDIOLOGY							
UNITED STATES	\$	3,673	\$	3,271	12.3 %	— %	12.3 %
INTERNATIONAL		3,036		2,662	14.1 %	2.1 %	16.2 %
WORLDWIDE	\$	6,709	\$	5,932	13.1 %	0.9 %	14.0 %
PERIPHERAL INTERVENTIONS							
UNITED STATES	\$	1,135	\$	1,048	8.3 %	— %	8.3 %
INTERNATIONAL		975		850	14.6 %	3.2 %	17.8 %
WORLDWIDE	\$	2,110	\$	1,899	11.1 %	1.4 %	12.6 %



Appendix A - Net Sales Information

Net Sales Growth

Total BSC Net Sales Growth	Year Ended December 31,					5-Year Average
	2023	2022	2021	2020	2019	
Percentage change in net sales, as reported	12.3 %	6.7 %	19.9 %	(7.7)%	9.3 %	8 %
Impact of foreign currency fluctuations	0.8 %	4.4 %	(1.3)%	(0.1)%	1.8 %	
Percentage change in net sales, operational	13.1 %	11.1 %	18.7 %	(7.8)%	11.1 %	9 %
Impact of recent acquisitions/divestitures	(0.8)%	(2.4)%	0.3 %	(3.5)%	(3.8)%	
Percentage change in net sales, organic	12.3 %	8.7 %	18.9 %	(11.3)%	7.3 %	7 %



Appendix B

Additional Information - Statement of Operations



Appendix B - Statement of Operations

Profitability Margins

	Three Months Ended		
Adjusted Gross Margin	12/31/2023	12/31/2022	Basis Points Change
Gross Margin, as reported	69.2 %	68.8 %	40
Non-GAAP adjustments	1.2 %	1.7 %	
Gross Margin, adjusted	70.4 %	70.5 %	(10)

	Three Months Ended		
Adjusted Operating Margin	12/31/2023	12/31/2022	Basis Points Change
Operating Margin, as reported	15.7 %	12.4 %	330
Non-GAAP adjustments	10.9 %	13.3 %	
Operating Margin, adjusted	26.6 %	25.7 %	90

	Year Ended		
Adjusted Gross Margin	12/31/2023	12/31/2022	Basis Points Change
Gross Margin, as reported	69.5 %	68.8 %	70
Non-GAAP adjustments	1.2 %	1.7 %	
Gross Margin, adjusted	70.7 %	70.5 %	20

	Year Ended		
Adjusted Operating Margin	12/31/2023	12/31/2022	Basis Points Change
Operating Margin, as reported	16.5 %	13.0 %	350
Non-GAAP adjustments	9.8 %	12.6 %	
Operating Margin, adjusted	26.3 %	25.6 %	70



Appendix C

Additional Non-GAAP Reconciliations



Appendix C - Additional Non-GAAP Reconciliations

in millions	Three Months Ended		Year Ended	
	12/31/2023	12/31/2022	12/31/2023	12/31/2022
Adjusted Free Cash Flow				
Operating cash flow, reported	\$ 957	\$ 807	\$ 2,503	\$ 1,526
Purchases of property, plant and equipment and internal use software	(267)	(212)	(711)	(588)
Proceeds on disposals of property, plant and equipment	—	1	4	12
Free Cash Flow	691	597	1,796	949
Restructuring and restructuring-related payments	41	34	150	144
Acquisition-related payments	97	61	314	329
Certain EU MDR implementation-related payments	16	19	69	71
Special tax payments (refunds/credits)	30	68	112	290
Certain litigation-related settlements	12	(4)	(13)	282
Adjusted Free Cash Flow	\$ 886	\$ 776	\$ 2,428	\$ 2,066

Estimated Free Cash Flow (in billions)	FY 2024
Cash provided by (used for) operating activities	\$ ~2.7
Purchases of property, plant and equipment and internal use software	(0.7)
Free Cash Flow	\$ ~2.0

Estimated FY 2024 free cash flow includes approximately \$800 million of expected payments related to acquisitions, restructuring, litigation and other special items



Appendix C - Additional Non-GAAP Reconciliations

(in millions)	Q4 2023	Q4 2022	As Reported Basis	Impact of Foreign Currency Fluctuations	Operational Basis	Impact of Recent Acquisitions/ Divestitures	Organic Basis
ENDOSCOPY	\$ 645	\$ 571	12.9 %	(0.7) %	12.2 %	(1.4) %	10.8 %
UROLOGY	527	477	10.5 %	(0.5) %	9.9 %	— %	9.9 %
NEUROMODULATION	269	249	8.0 %	(0.5) %	7.5 %	(4.9) %	2.6 %
MEDSURG	1,441	1,297	11.1 %	(0.6) %	10.5 %	(1.6) %	8.9 %
ICTx	614	561	9.3 %	0.2 %	9.5 %	— %	9.5 %
WATCHMAN	345	280	22.9 %	0.0 %	22.9 %	— %	22.9 %
CARDIAC RHYTHM MANAGEMENT	553	521	6.2 %	(0.8) %	5.4 %	— %	5.4 %
ELECTROPHYSIOLOGY	240	167	43.9 %	(0.8) %	43.1 %	— %	43.1 %
CARDIOLOGY	1,751	1,529	14.5 %	(0.3) %	14.2 %	— %	14.2 %
PERIPHERAL INTERVENTIONS	533	476	12.1 %	0.1 %	12.2 %	(2.1) %	10.2 %
CARDIOVASCULAR	2,285	2,005	13.9 %	(0.2) %	13.8 %	(0.5) %	13.3 %
	3,725	3,302	12.8 %	(0.4) %	12.5 %	(0.9) %	11.6 %
OTHER [†]	—	(60)	(100.0) %	— %	(100.0) %	— %	(100.0) %
WORLDWIDE NET SALES	\$ 3,725	\$ 3,242	14.9 %	(0.4) %	14.5 %	(0.9) %	13.6 %

† In 2022, this reflects sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments, or considered by our CODM for resource allocation and decision-making purposes. In 2023, these sales reserves were allocated to reportable segments.



Appendix C - Additional Non-GAAP Reconciliations

(in millions)	FY 2023	FY 2022	As Reported Basis	Impact of Foreign Currency Fluctuations	Operational Basis	Impact of Recent Acquisitions/ Divestitures	Organic Basis
ENDOSCOPY	\$ 2,482	\$ 2,221	11.7 %	0.6 %	12.3 %	(1.2)%	11.1 %
UROLOGY	1,964	1,773	10.8 %	0.4 %	11.1 %	— %	11.1 %
NEUROMODULATION	976	917	6.4 %	0.3 %	6.7 %	(1.3)%	5.3 %
MEDSURG	5,422	4,911	10.4 %	0.4 %	10.8 %	(0.8)%	10.0 %
ICTx	2,417	2,228	8.4 %	2.0 %	10.4 %	— %	10.4 %
WATCHMAN	1,274	1,019	25.1 %	0.3 %	25.4 %	— %	25.4 %
CARDIAC RHYTHM MANAGEMENT	2,218	2,100	5.6 %	0.2 %	5.9 %	— %	5.9 %
ELECTROPHYSIOLOGY	800	585	36.7 %	0.6 %	37.3 %	(4.6)%	32.7 %
CARDIOLOGY	6,709	5,932	13.1 %	0.9 %	14.0 %	(0.5)%	13.6 %
PERIPHERAL INTERVENTIONS	2,110	1,899	11.1 %	1.4 %	12.6 %	(1.6)%	10.9 %
CARDIOVASCULAR	8,819	7,831	12.6 %	1.1 %	13.7 %	(0.7)%	12.9 %
	14,240	12,742	11.8 %	0.8 %	12.6 %	(0.8)%	11.8 %
OTHER [†]	—	(60)	(100.0)%	— %	(100.0)%	— %	(100.0)%
WORLDWIDE NET SALES	\$ 14,240	\$ 12,682	12.3 %	0.8 %	13.1 %	(0.8)%	12.3 %

† In 2022, this reflects sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments, or considered by our CODM for resource allocation and decision-making purposes. In 2023, these sales reserves were allocated to reportable segments.



Appendix C - Additional Non-GAAP Reconciliations

Reconciliation of Debt to Adjusted EBITDA (in millions)	Q1 2023	Q2 2023	Q3 2023	Q4 2023	12 Months Ended
					12/31/2023
Net income (loss)	\$ 314	\$ 270	\$ 504	\$ 504	\$ 1,592
Income tax (benefit) expense	131	156	105	1	393
Interest expense	65	70	66	65	265
Interest income	(6)	(1)	(5)	(9)	(22)
Depreciation expense	82	88	93	104	367
Amortization expense	203	210	208	208	828
EBITDA	787	792	971	873	3,424
Non-GAAP Adjustments					
Restructuring and restructuring-related net charges (credits)	44	42	47	52	185
Goodwill and other intangible asset impairment charges	—	57	1	—	58
Investment portfolio net losses (gains)	21	(2)	2	(0)	21
Acquisition/divestiture - related net charges (credits)	59	118	66	129	373
Litigation-related net charges (credits)	—	—	(111)	—	(111)
EU MDR implementation costs	16	20	17	16	69
Adjusted EBITDA	\$ 928	\$ 1,028	\$ 991	\$ 1,070	\$ 4,017
Debt					\$ 9,102
Debt to Adjusted EBITDA					2.3x



Appendix C - Additional Non-GAAP Reconciliations

Adjusted Tax Rate	Three Months Ended	Year Ended
	12/31/2023	12/31/2023
Tax Rate, as reported	0.3 %	19.8 %
Non-GAAP adjustments	9.7 %	(8.6) %
Tax Rate, adjusted	10.0 %	11.2 %
Discrete tax items	4.6 %	2.7 %
Tax rate, operational	14.6 %	13.9 %

Estimated Tax Rate	FY 2024
Tax Rate, as reported	19 %
Non-GAAP adjustments	(6) %
Tax Rate, adjusted	13 %
Discrete tax items	1 %
Tax Rate, operational	14 %

Estimated Adjusted Below-the-Line Expenses <i>(in millions)</i>	FY 2024
Below-the-line expenses, as reported	\$ 330
Non-GAAP adjustments	—
Below-the-line expenses, adjusted	\$ 330



Appendix C - Additional Non-GAAP Reconciliations

Adjusted Operating Margin - by Segment	Three Months Ended December 31, 2022	
	MedSurg	Cardiovascular
Operating Margin, as reported	33.0 %	24.1 %
Non-GAAP adjustments	(1.1) %	(1.1) %
Operating Margin, adjusted	31.9 %	23.0 %

Adjusted Operating Margin - by Segment	Three Months Ended December, 31 2023	
	MedSurg	Cardiovascular
Operating Margin, as reported	35.3 %	24.7 %
Non-GAAP adjustments	0.1 %	0.1 %
Operating Margin, adjusted	35.4 %	24.8 %

Watchman U.S. Net Sales Growth	Three Months Ended 12/31/2023
Net sales growth, as reported	23 %
Impact of foreign currency fluctuations	— %
Net sales growth, operational	23 %
Impact of acquisitions/divestitures	— %
Net sales growth, organic	23 %

Net Sales Growth	2024E - 2026E (CAGR) ¹
Net sales growth, as reported	
Impact of foreign currency fluctuations	
Net sales growth, operational	
Impact of acquisitions/divestitures	
Net sales growth, organic	8.0 - 10.0%

1 - Components of the reconciliation of revenue growth, on an as reported and operational basis are not currently available without unreasonable efforts on a forward-looking basis because certain significant information necessary for such reconciliations is unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts.



Appendix C - Additional Non-GAAP Reconciliations

Latin America Net Sales Growth	Three Months Ended 12/31/2023	Year Ended 12/31/2023
Net sales growth, as reported	27 %	23 %
Impact of foreign currency fluctuations	(10)%	(6)%
Net sales growth, operational	17 %	17 %

Electrophysiology U.S. Net Sales Growth	Three Months Ended 12/31/2023
Net sales growth, as reported	40 %
Impact of foreign currency fluctuations	— %
Net sales growth, operational	40 %
Impact of acquisitions/divestitures	— %
Net sales growth, organic	40 %

Electrophysiology International Net Sales Growth	Three Months Ended 12/31/2023
Net sales growth, as reported	47 %
Impact of foreign currency fluctuations	(1)%
Net sales growth, operational	46 %
Impact of acquisitions/divestitures	— %
Net sales growth, organic	46 %

China Net Sales Growth	Year Ended 12/31/2023
Net sales growth, as reported	20 %
Impact of foreign currency fluctuations	6 %
Net sales growth, operational	26 %



BSX: Acronym Reference Guide

AF	Atrial Fibrillation
CODM	Chief Operating Decision Maker
CRM	Cardiac Rhythm Management
DIOH	Days Inventory on Hand
DSO	Days Sales Outstanding
EBITDA	Earnings Before Interest, Taxes, Depreciation, and Amortization
Endo	Endoscopy
EP	Electrophysiology
EPS	Earnings per Share
FDA	Food and Drug Administration
FY	Full Year
GAAP	Generally Accepted Accounting Principles
HCC	Hepatocellular Carcinoma
ICTx	Interventional Cardiology Therapies
LAAC	Left Atrial Appendage Closure
NM	Neuromodulation
PFA	Pulsed Field Ablation
PI	Peripheral Interventions
Uro	Urology